Predictability of response to endocrine ablation in breast cancer.
Carcinoma of the breast remains the most common and most frequently lethal form of cancer in women. In far-advanced disease, endocrine manipulation remains the major modality of treatment. Recent advances have shown that approximately 40% of breast cancers contain estradiol receptors in their cytoplasm. The presence or absence of these receptors is a good indicator of whether or not the patient will respond to endocrine ablation.
D000315:Adrenalectomy; D000818:Animals; D001940:Breast / Q000254:growth & development; D001943:Breast Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D002352:Carrier Proteins; D002369:Castration; D004967:Estrogens / Q000502:physiology; D005260:Female; D006801:Humans; D007016:Hypophysectomy; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D008408:Mastectomy; D011374:Progesterone / Q000502:physiology; D011388:Prolactin / Q000502:physiology; D051381:Rats; D011956:Receptors, Cell Surface
D002352:Carrier Proteins; D004967:Estrogens; D011956:Receptors, Cell Surface; D011374:Progesterone; D011388:Prolactin